FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL							
OMB Number:	3235-0287						
Estimated average burden							
hours ner resnonse:	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Ricks David A</u>					2. Issuer Name and Ticker or Trading Symbol ELI LILLY & Co [LLY]								(Check a	tionship of Reporting Person(s) to Issuer all applicable) Director 10% Owner			·	
(Last) (First) (Middle) LILLY CORPORATE CENTER					3. Date of Earliest Transaction (Month/Day/Year) 02/01/2021								_ x	X Officer (give title below) Other (specify below) President & CEO				
(Street) INDIANAPOLIS	IN		285		4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individ	Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City) (State) (Zip) Table ! - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3)			2. Tra	2. Transaction		2A. Deemed Execution Date, if any		3. Transaction 4. Securit		rities Acquired (A) or Dispos rr. 3, 4 and 5)		sposed Of	d Of 5. Amount of Sec Beneficially Own Following Report		6. Ownership Form: Direct (D) or ndirect (I) (Instr. 4)	7. Nature of Indirect Beneficial		
							(Month/Day/Year)	Code	v	Amount		(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)			Ownership (Instr. 4)	
Common Stock				02/	/01/2021			M		75,3	387	A	\$ <mark>0</mark>	343,639		D		
Common Stock				02/	/01/2021			F		33,7	738	D	\$207.97	309,901	1	D		
Common Stock														6,931		I	401(k)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Se Underlying Derivative Sec 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficia Owned Following	Ownership Form: Direct (D) or Indirect (I)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	/ (A) (D)		Date Exercisa		xpiration ate Title			Amount or Number of Shares		Reported Transactio (Instr. 4)	' ' '		
Restricted Stock Unit	(1)	02/01/2021		M			75,387	02/01/20	021 0	2/01/2021	Comi	mon Stock	75,387	\$0	0	D		

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock.

Remarks:

Crystal T. Williams for David A. Ricks, authorization on file

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

David A. Ricks Lilly Corporate Center Indianapolis, Indiana 46285

Securities and Exchange Commission Washington, D.C. 20549

Authorization Regarding Reporting Forms

I hereby authorize and designate the following persons to sign and file with the Commission on my behalf Forms 3, 4, and 5(including any amenda

Anat Hakim, Lilly Corporate Center, Indianapolis, Indiana

Crystal T. Williams, Lilly Corporate Center, Indianapolis, Indiana

Erin Conway, Lilly Corporate Center, Indianapolis, Indiana

This authorization and designation shall remain in effect until a written revocation is signed by me and provided to the Commission.

Date: January 5, 2021

/s/ David A. Ricks